Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (827)	5/19/1999 8:46:00 AM
From: the Chief	Read Replies (2) \| Respond to of 2344

"NP" is National Post in Canada NP says Biomira falls, analysts maintain "buy" rating Biomira Inc BRA-TSE Shares issued 44,000,000 May 18 close $5.80 Wed 19 May 99 In the News The National Post reports in its Wednesday edition that pharmaceutical company Biomira Inc.'s stock fell 15.7 per cent yesterday following news on Monday that a study suggested treatment with Biomira's Theratope cancer vaccine following autologous stem cell transplant increases survival and decreases relapse in ovarian and breast cancer patients. The share price reached $7.85 last week, its highest level in six months. Yesterday, Ezra Lwowski, an analyst at Yorkton Securities Inc., maintained a "buy" on the stock, adding that his target price of $6.50 is under review. Andre Uddin, an analyst at Merrill Lynch & Co., also maintained a near-term "buy" rating with a 12-month target price of $10. the Chief